Management of Patients with Overactive Bladder in Brazil: A Retrospective Observational Study Using Data From the Brazilian Public Health System

Abstract

Introduction:In Brazil, current data on the use of healthcare resources to manage individuals with overactive bladder (OAB) are lacking. This study aimed to characterize contemporary treatment and the economic burden among patients with OAB managed under the Brazilian public health system (Sistema Ú nico de Saú de [SUS]). within the SUS. These data provide a snapshot of the management of patients with OAB in Brazil, with the patients seeking treatment under SUS likely representing a more burdened subpopulation. Key Summary PointsWhy carry out this study?An accurate understanding of the economic burden of overactive bladder (OAB) requires knowledge of both disease prevalence and contemporary management practices.While some studies of the prevalence of OAB in Brazil exist, studies exploring treatment practices and economic burden in relation to OAB are lacking.This study sought to characterize contemporary treatment and the economic burden associated with the management of patients with OAB in the Brazilian public health system. What was learned from the study?This study helped highlight the undertreatment of OAB within the Brazilian public health system, and helped quantify healthcare resource use and associated costs among those actively managed for OAB within that system.

Electric nerve stimulation for overactive bladder: an umbrella review

“…Overactive bladder (OAB) is a clinical syndrome defined as urinary urgency, usually with high frequency and nocturia and with or without urgency urinary incontinence, in the absence of urinary tract infection or other obvious pathology [1]. Approximately 5–12% of children (5–10 years of age), 0.5% of older teenagers (16–18 years of age) and 11.8–30% of adults worldwide suffer from OAB [2,3]. Many studies and considerable clinical feedback have found that first-line therapy for OAB has poor compliance: such treatments include behavioral therapy, which requires a high degree of self-control and cognitive ability, and medication, which often has side effects such as dry mouth and headache.…”

Age-dependent effects of the β3 adrenoceptor agonist CL316,243 on human and rat detrusor muscle strips

“…What is the clinical implication of our study? A recent review clarified that anticholinergics and β 3 agonists showed similar efficacy, but tolerability issues clearly favoured the latter [ 31 ]. Since OAB is more prevalent in the elderly, reduced β 3 responsiveness of bladder smooth muscle cells could be of clinical interest, even though—at present—there is little evidence for this [ 36 ].…”

Current pharmacotherapy of overactive bladder

“…It is metabolized in the liver utilizing the cytochrome P450 enzyme system (CYP3A4), but a modest percentage undergoes renal excretion without additional metabolism raising the possibility that it could also work from the luminal side of the bladder (34,35). Oxybutynin: Oxybutynin is the oldest agent in use for OAB and remains as either the first or second most prescribed agent in many countries (36)(37)(38)(39). It is an antimuscarinic agent that also has strong independent musculotropic relaxant activity and local anesthetic activity (40,41).…”